This would be in line with the preclinical data for sGC modulators in HF, which have shown that these agents have been associated with blood pressure-independent reductions in cardiac fibrosis and left ventricular mass, improvements in endothelial dysfunction, and the preservation of renal function. This evidence concerns the gene SGCB and endothelial dysfunction.